You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海醫藥(02607.HK)斥2.6億元取得LT3001項目於中國大陸開發及銷售等獨佔權益
格隆匯 11-06 20:38

格隆匯11月6日丨上海醫藥(02607.HK)公告,2019 年 11 月 6 日,上海醫藥集團股份有限公司 與順天醫藥生技股份有限公司(中國台灣上市公司,股票代碼: 6535.TW,以下簡稱“順天醫藥”)簽訂《合作協議》,將出資人民幣 2.6 億元取得 LT3001 項目在中國大陸地區開發、生產和銷售等的獨佔權益  。

為豐富研發產品管線,進一步加強公司在心腦血管領域的市場地位,上海醫 藥與順天醫藥就 LT3001 項目開展合作。LT3001 屬於全球創新分子,目前正在美 國、台灣兩地開展針對急性缺血性腦卒中的多中心臨牀Ⅱ期試驗。 2019 年 11 月 6 日,上海醫藥與順天醫藥簽訂《合作協議》,將根據產品研 發進度,向順天醫藥支付首付款以及後續研發里程碑款項合計不超過 26,000 萬 元,產品上市後再支付相應的銷售提成,以獲取在中國大陸地區開發、生產和銷 售等的獨佔權益。

LT3001 屬於全球首創結合靶向溶栓和腦神經保護功能的急性腦卒中治療新藥。前期動物實驗及臨牀Ⅰ期試驗結果顯示,與已上市的溶栓藥物相比,LT3001 在不增加出血風險的前提下具有延長治療時間窗的極大潛力,同時可以清除自由 基,保護腦神經細胞,兼具減輕再灌注損傷和腦水腫、改善預後的潛在優勢。 

LT3001 作為一款具有廣闊市場前景的 First-in-Class 新藥,其引進將進一步 豐富上海醫藥的創新研發管線,結合公司在重點聚焦的心腦血管領域成熟的生產 和銷售資源,有望為業績提供新的增長動力。該產品已在美國和台灣啟動第Ⅱ期 臨牀試驗,上海醫藥將於本次簽約後作為申報主體在中國地區提交臨牀申請,加 入國際多中心臨牀試驗,共享全球數據,通過共同開發的合作形式加快產品開發 進程,縮短上市週期。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account